Clinical and Cost Effectiveness of Neuromodulation Devices in the Treatment of Headaches: Focus on Non-invasive Therapies
Primary headaches are a common indication for review in neurology clinics. Migraines, tension-type headaches and trigeminal-autonomic cephalalgia (TAC) are the most common primary headache disorders. Migraines can cause significant functional disability and cluster headaches (the commonest TAC) are one of the worst pains known to mankind. Pharmacological treatment has been the standard for both abortive and prophylactic intervention for many years, but there are patients who are refractory to medical therapy and there are others who cannot take such medications because of co-morbidities or cannot tolerate the side effects.
- 1.NICE. NICE. How NICE measures value for money in relation to public health interventions. 2013. www.nice.org.uk/Media/Default/guidance/LGB10-Briefing-20150126.pdf
- 5.NICE TAG. NICE. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Technology appraisal guidance [TA260]. 2012. https://www.nice.org.uk/guidance/ta260/resources/botulinum-toxin-typea-for-the-prevention-of-headaches-in-adults-with-chronic-migraine-pdf-82600545273541
- 6.Bhola R, Kinsella E, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535.Google Scholar
- 16.Gaul C, Magis D, Liebler E, Straube A. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. J Headache Pain. 2017;18(1):22.CrossRefGoogle Scholar
- 22.Kinfe T, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon B, Vatter H. Cervical non-invasive vagus nerve stimulation (nVNS) for preventative and acute treatment of episodic and chronic migrain and migraine-associated sleep disturbance: preliminary findings from a prospective observational cohort study. J Headache Pain. 2015;16:101.CrossRefGoogle Scholar
- 27.Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(1):95.CrossRefGoogle Scholar
- 30.Vikelis M, Dermitzakis E, Spingos K, Vasiliadis G, Vlachos G, Kararizou E. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. BMC Neurol. 2017;17:97.CrossRefGoogle Scholar
- 35.Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225. https://doi.org/10.1002/14651858.CD003225.pub2.